The Sanofi Ventures-backed vaccine development company has listed on Nasdaq, with its shares rising on the first day of trading.
Icosavax, a US-based vaccine developer backed by pharmaceutical firm Sanofi, floated in a $182m initial public offering on Thursday on the Nasdaq Global Select Market.
The company issued some 12 million shares having priced them in the middle of the IPO’s $14 to $16 range. They opened at $29 each before closing at $35, representing a 133% increase.
Spun out of University of Washington’s Institute for Protein Design, Icosavax is developing vaccines for respiratory illnesses using virus-like particles. Its…
